ArticleEuropean journal of nuclear medicine and molecular imaging2021
Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants.
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07586046 (A Prospective Dose-Escalation Study to Define an Ablative Dose of Yttrium-90 Transarterial Radioembolization Using Advanced Dosimetry and Functional MRI), which is not on this map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Dose-Escalation Study to Define an Ablative Dose of Yttrium-90 Transarterial Radioembolization Using Advanced Dosimetry and Functional MRI (MARGIN Study)
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.
- Selective internal radiation therapy of metastatic breast cancer to the liver: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.European journal of nuclear medicine and molecular imaging · 2023Trial
- Accuracy and Safety of Scout Dose Resin Yttrium-90 Microspheres for Radioembolization Therapy Treatment Planning: A Prospective Single-Arm Clinical Trial.Journal of vascular and interventional radiology : JVIR · 2022Trial
- Histopathological outcomes of CT-guided high-dose-rate interstitial brachytherapy for HCC and predictive accuracy of the LI-RADS Radiation Treatment Response Algorithm v2024.European radiology · 2026Article
- Radiation segmentectomy for hepatocellular carcinoma: redefining the limits of curative-intent therapy.The British journal of radiology · 2026Review
- Intrahepatic cholangiocarcinoma treated with glass yttrium-90 radioembolization: A histopathologic study.European journal of nuclear medicine and molecular imaging · 2026Article
- Real World Outcomes of Prescribed Ablative Dose Yttrium-90 Resin Selective Internal Radiation Therapy of Hepatocellular Carcinoma.World journal of nuclear medicine · 2026Article
- Review
- Review
- Comparison of pre-therapeutic [European journal of nuclear medicine and molecular imaging · 2026Article
- Gastrointestinal Safety of Left Hepatic Lobe Radiation Segmentectomy-Reassuring Data with Room for Further Investigation.Cardiovascular and interventional radiology · 2026Article
- Single-system outcomes after adopting yttrium-90 radioembolization with personalized dosimetry as the primary treatment approach for unresectable, solitary hepatocellular carcinoma.ESMO gastrointestinal oncology · 2026Article
- Yttrium-90 Transarterial Radioembolization for Intrahepatic Cholangiocarcinoma: A Comprehensive Review.Journal of gastrointestinal cancer · 2026Review
- Role of Liver Function in the Multiparametric Assessment of Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2026Review
- Toward Digital Twins for Optimal Radioembolization.PET clinics · 2026Review
- Histopathologic outcomes of hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 resin microspheres.European journal of nuclear medicine and molecular imaging · 2026Article
- Tumor Burden Thresholds Associated with Successful Downstaging After Yttrium-90 Radioembolization in Hepatocellular Carcinoma Beyond UCSF Criteria.Journal of hepatocellular carcinoma · 2026Article
- Understanding Current Trends and Advances in Transarterial Radioembolization Dosimetry.Diagnostics (Basel, Switzerland) · 2025Review
- Voxel-based dosimetry for predicting treatment response to transarterial radioembolization in hepatocellular carcinoma: significance of intratumoral dose distribution.EJNMMI physics · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo study the correlation between absorbed perfused liver dose using Y90 radioembolization and degree of hepatocellular carcinoma (HCC) necrosis in liver explants in a multicenter cohort analysis
methodsA retrospective analysis of 45 HCC patients treated between 2014 and 2017 is presented. Inclusion criteria were treatment-naïve solitary HCC ≤ 8 cm and Child-Pugh A liver status using the radiation segmentectomy approach. All patients underwent liver resection or transplantation (LT). Liver explants were examined per institutional routine protocols to assess histopathological viability of HCC. Tumor pathological necrosis was classified into complete (100% necrosis), extensive (> 50% and ≤ 99%) necrosis, and partial (< 50%) necrosis. Absorbed perfused liver doses were estimated using MIRD calculations. Associations between dose and degree of necrosis were studied.
resultsThirty-four (76%) patients underwent LT, and 11 (24%) patients underwent hepatic resection. Median radiation dose was 240 (IQR: 136-387) Gy. Thirty (67%) patients had complete pathologic necrosis (CPN) at explant, while 10 (22%) and 5 (11%) had extensive and partial necrosis, respectively. There were significant differences among perfused liver doses that exhibited partial, extensive, and complete necrosis (p = 0.001). Twenty-four out of twenty-eight (86%) patients who had dose > 190 Gy achieved CPN, while 11/17 (65%) who had < 190 Gy did not (Fisher's exact test; p = 0.001). Using binary logistic regression, only absorbed radiation dose was significantly associated with CPN (p = 0.01), while tumor size was not (p = 0.35). All patients receiving > 400 Gy exhibited CPN.
conclusionRadiation segmentectomy for early HCC with ablative dosing > 400 Gy results in CPN. This represents the new standard target dose for radiation segmentectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.